Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Double DES in bifurcations, double thrombosis risk

Original title: Late Thrombosis After Double Versus Single Drug-Eluting Stent in the Treatment of Coronary Bifurcations A Meta-analysis of Randomized and Observational Studies. Reference: Marco Zimarino et al. J Am Coll Cardiol Intv 2013. Article in press.

In the era of drug-eluting stents, (DES), several randomized and observational studies have been conducted trying to find the best strategy to deal with a bifurcation. Since most of the individual studies failed to arrive at any definitive conclusions, meta-analyzes were performed to understand the association between a double drug-eluting stent technique at a bifurcation and an increased risk of stroke but the mechanisms behind this risk were not clear.

The hypothesis of this study is that the increased risk on events using a double stent would be related to the increased rate of thrombosis. Twelve studies, (five randomized trials and seven observational), were analyzed in this meta-analysis with a total of 6,961 patients, of whom 1,868 received DES and 5,093 one single DES to treat bifurcation lesions. 

The double DES group had a higher risk of thrombosis compared with the single DES group, (RR 2.31, 95% CI, 1.33 to 4.03). This significantly increased the risk of thrombosis according primarily to observational studies, while randomized studies only showed a trend in this direction. There was also an increased risk of stroke in the double stent group, (RR 1.86, 95% CI, 1.34 to 2.35), and this significant difference was observed in all jobs. Despite the above, the all-cause mortality was similar to target vessel revascularization

Conclusion: 

Routinely, two DES implants to treat a bifurcation is associated with an increased risk of myocardial infarction compared with the technique of a single stent in the main vessel and a provisional stent in the accessory vessel. The higher incidence of infarction appears to be related to increased thrombosis. 

Comment: 

With bifurcations, as ever, the conclusion is again less is more. The second stent should always be implemented taking into account that we are doubling the chance of thrombosis and also doubling the chance of restenosis. If it is necessary, we must consider a more aggressive platelet aggregation

SOLACI.ORG

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

HERA-TAVI: Intra-Annular vs Supra-Annular Valves in TAVI

The HERA-TAVI study is an international multicenter registry that compared the clinical and hemodynamic outcomes of contemporary self-expanding transcatheter heart valves with intra-annular (IA)...

DOUBLE-CHOICE: Lower Pacemaker Implantation Rates with ACURATE neo2 Compared with Evolut in Patients Undergoing TAVI

The DOUBLE-CHOICE trial is a multicenter, randomized, controlled study conducted in Germany to evaluate the performance of next-generation transcatheter heart valves and different anesthesia...

GLUCO-TAVI | Can Glucocorticoids Reduce the Need for Permanent Pacemaker Implantation After TAVI?

Despite the expansion of transcatheter aortic valve implantation (TAVI) indications, cardiac conduction disturbances (CCD) and the need for permanent pacemaker implantation (PPI) remain the...